Evaluation of Subcutaneous Immunoglobulin Product Cutaquig in Terms of Safety and Efficacy in the Treatment of Patients With Primary Immunodeficiencies

NCT05986734 · clinicaltrials.gov ↗

UNKNOWN

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Primary Immunodeficiency Diseases (PID)

Interventions

DRUG: Cutaquig

Sponsor

Federal Research Institute of Pediatric Hematology, Oncology and Immunology